Cholestasis after very preterm birth was associated with adverse neonatal outcomes but no significant long-term liver disease: A population-based study.
bronchopulmonary dysplasia
chronic liver disease
neonatal intensive care
neonatal mortality
retinopathy of prematurity
Journal
Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
13
03
2020
revised:
09
05
2020
accepted:
04
06
2020
pubmed:
12
6
2020
medline:
15
5
2021
entrez:
12
6
2020
Statut:
ppublish
Résumé
To describe outcome linked to neonatal cholestasis in a defined cohort of very preterm infants. Population-based retrospective case-control study of preterm infants, gestational age <30 weeks, surviving for 28 days, in Stockholm County. Cholestasis was defined as conjugated bilirubin ≥30 μmol/L exceeding 20% of total level at least twice and graded as high if exceeding 100 μmol/L. Cholestatic cases were matched on gestational week with two non-cholestatic controls. The incidence rate of cholestasis was 37/250 (14.8%), with increasing rates in lower gestational weeks. Perinatal factors associated with cholestasis were pre-eclampsia and being born small for gestational age. Cholestatic infants had three times more bronchopulmonary dysplasia and eight times more retinopathy of prematurity. The mortality was 13.5% in cholestatic infants versus 2.7% in controls (P = .040). All deceased cholestatic infants had high-grade cholestasis. No surviving infants developed chronic liver disease by 10 years of age. Cholestasis was common in very preterm infants and linked to disease severity and adverse outcome. Cholestasis may be an independent risk factor for bronchopulmonary dysplasia and retinopathy of prematurity and more severe cholestasis associated with increased mortality. Cholestasis was not associated with chronic liver disease later in childhood.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
141-148Informations de copyright
© 2020 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
Références
Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the north american society for pediatric gastroenterology, hepatology, and nutrition and the European society for pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr. 2017;64(1):154-168.
Koseesirikul P, Chotinaruemol S, Ukarapol N. Incidence and risk factors of parenteral nutrition-associated liver disease in newborn infants. Pediatr Int. 2012;54(3):434-436.
Lee HH, Jung JM, Nam SH, Lim G, Chung ML. Risk factor analysis of parenteral nutrition-associated cholestasis in extremely low birth weight infants. Acta Paediatr. 2016;105(7):e313-e319.
Lee SM, Namgung R, Park MS, et al. Parenteral nutrition associated cholestasis is earlier, more prolonged and severe in small for gestational age compared with appropriate for gestational age very low birth weight infants. Yonsei Med J. 2013;54(4):839-844.
Tufano M, Nicastro E, Giliberti P, Vegnente A, Raimondi F, Iorio R. Cholestasis in neonatal intensive care unit: incidence, aetiology and management. Acta Paediatr. 2009;98(11):1756-1761.
Christensen RD, Henry E, Wiedmeier SE, Burnett J, Lambert DK. Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease. J Perinatol. 2007;27(5):284-290.
Costa S, Maggio L, Sindico P, Cota F, De Carolis MP, Romagnoli C. Preterm small for gestational age infants are not at higher risk for parenteral nutrition-associated cholestasis. J Pediatr. 2010;156(4):575-579.
Robinson DT, Ehrenkranz RA. Parenteral nutrition-associated cholestasis in small for gestational age infants. J Pediatr. 2008;152(1):59-62.
Baserga MC, Sola A. Intrauterine growth restriction impacts tolerance to total parenteral nutrition in extremely low birth weight infants. J Perinatol. 2004;24(8):476-481.
Alison M, Biran V, Tanase A, et al. Quantitative shear-wave elastography of the liver in preterm neonates with intra-uterine growth restriction. PLoS One. 2015;10(11):e0143220.
Kapoor V, Malviya MN, Soll R. Lipid emulsions for parenterally fed term and late preterm infants. Cochrane Database Syst Rev. 2019;6:CD013171.
Teng J, Arnell H, Bohlin K, Nemeth A, Fischler B. Impact of parenteral fat composition on cholestasis in preterm infants: a population based study. J Pediatr Gastroenterol Nutr. 2015;60(6):702-707.
Habli M, Levine RJ, Qian C, Sibai B. Neonatal outcomes in pregnancies with preeclampsia or gestational hypertension and in normotensive pregnancies that delivered at 35, 36, or 37 weeks of gestation. Am J Obstet Gynecol. 2007;197:406.e1-406.e7.
Wikstrom AK, Stephansson O, Cnattingius S. Previous preeclampsia and risks of adverse outcomes in subsequent nonpreeclamptic pregnancies. Am J Obstet Gynecol. 2011;204(2):148.e1-148.e6.
McElrath TF, Allred EN, Van Marter L, Fichorova RN, Leviton A, Investigators ES. Perinatal systemic inflammatory responses of growth-restricted preterm newborns. Acta Paediatr. 2013;102(10):e439-e442.
Leviton A, Allred EN, Fichorova RN, et al. Antecedents of inflammation biomarkers in preterm newborns on days 21 and 28. Acta Paediatr. 2016;105(3):274-280.
Jensen EA, Foglia EE, Dysart KC, et al. Adverse effects of small for gestational age differ by gestational week among very preterm infants. Arch Dis Child Fetal Neonatal Ed. 2019;104(2):F192-F198.
Bose C, Van Marter LJ, Laughon M, et al. Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. Pediatrics. 2009;124(3):e450-e458.
Hansen AR, Barnes CM, Folkman J, McElrath TF. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr. 2010;156(4):532-536.
Lal CV, Ambalavanan N. Biomarkers, early diagnosis, and clinical predictors of bronchopulmonary dysplasia. Clin Perinatol. 2015;42(4):739-754.
Ambalavanan N, Carlo WA, D'Angio CT, et al. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics. 2009;123(4):1132-1141.
Podraza W, Michalczuk B, Jezierska K, et al. Correlation of retinopathy of prematurity with bronchopulmonary dysplasia. Open Med (Wars). 2018;13:67-73.
DeMauro SB, Kilpatrick LE, Gerdes JS, Abbasi S. Early inflammatory markers for prediction of cholestasis in very-low-birth-weight infants. Neonatology. 2012;102(3):229-234.
Pawlik D, Lauterbach R, Walczak M, Hurkala J, Sherman MP. Fish-oil fat emulsion supplementation reduces the risk of retinopathy in very low birth weight infants: a prospective, randomized study. JPEN J Parenter Enteral Nutr. 2013;38(6):711-716.
Shah J, Jefferies AL, Yoon EW, Lee SK, Shah PS, Canadian NN. Risk factors and outcomes of late-onset bacterial sepsis in preterm neonates born at < 32 weeks' gestation. Am J Perinatol. 2015;32(7):675-682.
Yan W, Hong L, Wang Y, et al. Retrospective dual-center study of parenteral nutrition-associated cholestasis in premature neonates: 15 years' experience. Nutr Clin Pract. 2017;32(3):407-413.
Wolf A, Pohlandt F. Bacterial infection: the main cause of acute cholestasis in newborn infants receiving short-term parenteral nutrition. J Pediatr Gastroenterol Nutr. 1989;8(3):297-303.
Khalil S, Shah D, Faridi MM, Kumar A, Mishra K. Prevalence and outcome of hepatobiliary dysfunction in neonatal septicaemia. J Pediatr Gastroenterol Nutr. 2012;54(2):218-222.
Mokha JS, Davidovics ZH, Maas K, Caimano MJ, Matson A. Fecal microbiomes in premature infants with and without parenteral nutrition-associated cholestasis. J Pediatr Gastroenterol Nutr. 2019;69(2):224-230.
Fujishiro J, Sugiyama M, Ishimaru T, et al. Direct hyperbilirubinemia in infants with congenital heart disease. Pediatr Int. 2018;60(2):179-182.